Anti-VEGF, A Biography: Part 3 (New Retina Radio)

Eyetube Podcasts

Content provided by Bryn Mawr Communications. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

6+ y ago 34:09

MP3

Archived series ("Inactive feed" status)

When? This feed was archived on January 15, 2021 22:53 (3+ y ago). Last successful fetch was on June 25, 2020 14:50 (4y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again.
Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD, to tell the latest chapter of anti-VEGF's biography.

199 episodes

#Science #Tech #Medicine #Bryn Mawr Communications #Informed Consent